GBP511, a Sarbecovirus-Targeted Vaccine Candidate,
Begins Clinical Trials in Australia

SK Bioscience has begun developing a universal vaccine designed to broadly prevent coronaviruses, including COVID-19.


On January 29, SK Bioscience announced that it has initiated global Phase 1 and 2 clinical trials in Australia for its vaccine candidate "GBP511," which targets the sarbecovirus family. Sarbecoviruses are a higher-order group that includes the COVID-19 virus, as well as not only currently circulating variants but also novel SARS-like coronaviruses that can be transmitted from animals to humans.

A researcher at SK Bioscience is conducting analytical experiments for vaccine development. SK Bioscience

A researcher at SK Bioscience is conducting analytical experiments for vaccine development. SK Bioscience

View original image

The clinical trial will involve approximately 368 adults aged 18 and older. In Phase 1, participants will receive two doses of the test vaccine?at low, medium, or high doses, with or without an adjuvant?administered 28 days apart. The safety, tolerability, and immunogenicity of the vaccine will then be evaluated in comparison with mRNA COVID-19 vaccines. In Phase 2, the trial will be expanded to include more participants, both adults and the elderly, to further assess immune responses and safety.


During the clinical process, SK Bioscience plans to evaluate the potential of GBP511 as a universal vaccine by confirming cross-immune responses against the entire sarbecovirus family, including COVID-19. The company stated its intention to establish a vaccine platform that covers the entire virus family, going beyond responses to specific variants.


GBP511 incorporates technology from SK Bioscience's synthetic antigen-based COVID-19 vaccine "Skycovione," which was commercialized in 2022. This is further combined with recombinant gene technology and nanoparticle design technology from the Institute for Protein Design (IPD) at the University of Washington. Skycovione has already demonstrated safety and immunogenicity through global clinical trials.



An Jaeyong, CEO of SK Bioscience, stated, "Developing a universal sarbecovirus vaccine is a challenge that must be addressed to prepare for the next pandemic. With the initiation of the GBP511 clinical trial, we will accelerate universal vaccine development and aim to become a leading company in the global vaccine market, leveraging our proactive infectious disease response capabilities."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing